Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices

Report on Business

Streetwise

Streetwise gives you news and analysis on Bay Street and the world of finance
available exclusively to subscribers of Globe Unlimited

Entry archive:

A Valeant effort: Growing drug maker can’t stop buying Add to ...

Subscribers Only

Don’t be discouraged if you have trouble determining Valeant Pharmaceuticals International Inc.’s true value. The drug maker’s acquisition pace makes it almost impossible to peg.

Since Valeant tied up with Biovail Corp. in 2010, the company has embarked on an ambitious acquisition spree, striking 21 deals worth more than $14-billion in a little over three years. Every time shareholders get a chance to catch a breather and assess the future, management goes hunting again. Now the executive team wants to team up with Bill Ackman on a brand new $47-billion deal.

Report Typo/Error

Follow on Twitter: @timkiladze

Next story

loading

Trending

loading

Most popular videos »

More from The Globe and Mail

Most popular